Scientific Sessions 2025  /  Exploring The Evidence: in Individuals with T2D and ASCVD  /  Exploring The Evidence: in Individuals with T2D and ASCVD. Provided by Voxmedia. This activity is supported by an educational grant from Novo Nordisk, Inc.
Logo

American Heart Association

  14
  0

Final ID:

Exploring The Evidence: in Individuals with T2D and ASCVD. Provided by Voxmedia. This activity is supported by an educational grant from Novo Nordisk, Inc.

  • Leiter, Lawrence  ( University of Toronto , Toronto , Ontario , Canada )
  • Mcguire, Darren  ( UT Southwestern , Dallas , Texas , United States )
  • Pratley, Richard  ( AdventHealth Orlando , Orlando , Florida , United States )
  • Pagidipati, Neha  ( DCRI , Durham , North Carolina , United States )
    • Author Disclosures:
    Lawrence Leiter: DO have relevant financial relationships ; Advisor:Abbott:Active (exists now) ; Speaker:GSK:Active (exists now) ; Advisor:Regeneron:Active (exists now) ; Other (please indicate in the box next to the company name):vTv (member of DSMB):Active (exists now) ; Other (please indicate in the box next to the company name):CRISPR (member of DSMB):Active (exists now) ; Advisor:Roche:Active (exists now) ; Advisor:General Medicine:Active (exists now) ; Other (please indicate in the box next to the company name):AstraZeneca (member of study Steering Committee:Past (completed) ; Advisor:Novartis:Active (exists now) ; Other (please indicate in the box next to the company name):Merck (member of study Steering Committee):Active (exists now) ; Advisor:Merck:Active (exists now) ; Other (please indicate in the box next to the company name):HLS Therapeutics (member of study Steering Committee):Active (exists now) ; Speaker:HLS Therapeutics:Active (exists now) ; Advisor:HLS Therapeutics:Active (exists now) ; Other (please indicate in the box next to the company name):Eli Lilly (member of study Steering Committee):Active (exists now) ; Speaker:Eli Lilly:Active (exists now) ; Advisor:Eli Lilly:Active (exists now) ; Speaker:Boehringer Ingelheim:Active (exists now) ; Advisor:Bayer:Active (exists now) ; Other (please indicate in the box next to the company name):Amgen (member of study Executive Committee):Active (exists now) ; Speaker:Amgen:Active (exists now) ; Advisor:Amgen:Active (exists now) | Darren McGuire: DO have relevant financial relationships ; Consultant:Lilly USA:Active (exists now) ; Consultant:Novartis:Active (exists now) ; Consultant:New Amsterdam:Active (exists now) ; Consultant:F. Hoffman La Roche:Active (exists now) ; Consultant:Regor:Active (exists now) ; Consultant:Metsera:Active (exists now) ; Consultant:Zealand:Active (exists now) ; Consultant:Alveus:Active (exists now) ; Consultant:Kalera:Active (exists now) ; Consultant:Neurotronic:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Consultant:Lexicon:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Boehringer Ingelheim:Active (exists now) | Richard Pratley: DO have relevant financial relationships ; Consultant:Abbott Laboratories; Gasherbrum Bio Inc.; Genprex; Getz Pharma:Active (exists now) ; Consultant:Verdiva Bio Dev Limited:Active (exists now) ; Speaker:Lilly USA LLC; Merck; Novo Nordisk:Active (exists now) ; Consultant:Lilly USA LLC; Novo Nordisk; RegeneronPfizer:Active (exists now) ; Research Funding (PI or named investigator):Endogenex Inc.; Sanofi:Active (exists now) ; Consultant:Corcept Therapeutics Incorporated; Rivus Pharmaceuticals Inc.:Active (exists now) ; Research Funding (PI or named investigator):Carmot Therapeutics; Fractyl; Metavention; Novo-Nordisk:Active (exists now) ; Consultant:Boehringer Ingelheim Pharmaceuticals Inc.:Active (exists now) ; Research Funding (PI or named investigator):Biomea Fusion; Dompe; Eli Lilly and Company:Active (exists now) ; Consultant:Bayer Healthcare Pharmaceuticals Inc.; Scholar Rock Inc.:Active (exists now) ; Consultant:Bayer AG; Endogenex Inc.; Hanmi Pharmaceutical Co.; Lexicon Pharmaceuticals:Active (exists now) ; Consultant:AstraZeneca Pharmaceuticals LP:Active (exists now) ; Consultant:Amgen Inc.; F. Hoffman-La Roche Ltd.:Active (exists now) ; Individual Stocks/Stock Options:Altanine Inc.:Active (exists now) ; Consultant:AbbVie Inc.; Eli Lilly and Company; Sun Pharmaceutical Industries:Active (exists now) | Neha Pagidipati: DO have relevant financial relationships ; Research Funding (PI or named investigator):Alnylam:Active (exists now) ; Consultant:Esperion:Active (exists now) ; Consultant:Eli Lilly:Active (exists now) ; Consultant:Corsera:Active (exists now) ; Consultant:Corcept:Active (exists now) ; Consultant:Boehringer Ingelheim:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Research Funding (PI or named investigator):Merck:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Active (exists now) ; Research Funding (PI or named investigator):Novartis:Active (exists now) ; Research Funding (PI or named investigator):Eli Lilly:Active (exists now) ; Research Funding (PI or named investigator):Boehringer Ingelheim:Active (exists now) ; Research Funding (PI or named investigator):Bayer:Active (exists now) ; Research Funding (PI or named investigator):Amgen:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Exploring The Evidence: in Individuals with T2D and ASCVD

Sunday, 11/09/2025 , 07:00PM - 08:30PM

Industry Satellite Symposia

More abstracts from these authors:
How are incretins PIONEERing metabolic care? Mechanisms of weight loss and risk factor reduction with incretin analogues

Nauck Michael, Drucker Daniel, Pratley Richard

Mechanisms underlying Diabetic Kidney Disease and CVD Risk

Tuttle Katherine, Pratley Richard

You have to be authorized to contact abstract author. Please, Login
Not Available